Thinking of joining a study?

Register your interest

Become a volunteer?

NCT05694312 | Recruiting | Autoimmune Hemolytic Anemia

Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL
Sponsor:

Italian Group of Adult Hematological Diseases

Brief Summary:

This is a multicenter, single arm, phase II study aimed at evaluating ibrutinib therapy for the treatment of AIHA in patients with CLL/SLL or CLL-like MBL.

Condition or disease

Autoimmune Hemolytic Anemia

Chronic Lymphocytic Leukemia

Small Lymphocytic Lymphoma

Monoclonal B-Cell Lymphocytosis CLL-Type

Intervention/treatment

Ibrutinib 420 mg

Phase

Phase 2

Detailed Description:

This is a multicenter, phase II study to assess the efficacy of ibrutinib for the treatment of AIHA in adult patients with CLL/SLL or CLL-like MBL. Patients will receive ibrutinib 420 mg/day PO for up to 12 cycles of 28 days in the absence of CLL progression or unacceptable toxicity. Every patient will be followed-up for 1 year after the completion of study treatment.}}

Study Type : Interventional
Estimated Enrollment : 45 participants
Masking : None (Open Label)
Primary Purpose : Treatment
Official Title : Ibrutinib for the Treatment of Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or CLL-like Monoclonal B-cell Lymphocytosis
Actual Study Start Date : November 24, 2023
Estimated Primary Completion Date : May 2025
Estimated Study Completion Date : November 2026
Arm Intervention/treatment

Experimental: Ibrutinib

Patients will receive ibrutinib 420 mg/day orally for up to 12 cycles of 28 days.

Drug: Ibrutinib 420 mg
Ages Eligible for Study: 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Criteria
Inclusion Criteria
  • Diagnosis of CLL/small lymphocytic lymphoma (SLL) or CLL-like monoclonal B-cell lymphocytosis (MBL) according to IWCLL guidelines.
  • Patients >18 years old
  • Active AIHA (wAIHA or CAD) that i) is relapsed after previous treatment with corticosteroids (with or without rituximab), or ii) is steroid-resistant (failure to obtain hematologic response within 3 weeks on at least 1 mg/kg predniso(lo)ne), or iii) is steroid-dependent (need to continue on predniso(lo)ne at a dose of >10 mg/day to maintain a response). AIHA is defined as: anemia (hemoglobin ≤10 g/dL; or hemoglobin >10 g/dL dependent on transfusions to maintain this level of hemoglobin) and laboratory evidence of hemolysis (presence of 3 of 4 markers: increased reticulocyte count, increased indirect bilirubin, increased lactate dehydrogenase, decreased haptoglobin) and positive DAT (either IgG DAT, C3 DAT or both).
  • Eligibility of patients with DAT-negative active AIHA should be confirmed by the Principal Investigator and co-Principal Investigator for the trial.
  • Signed written informed consent according to ICH/EU/GCP and national local laws.
Exclusion Criteria
  • Contraindication to ibrutinib therapy as per treating physician's discretion.
  • Contraindication to ibrutinib therapy as per ibrutinib data sheet (severe hepatic impairment, known allergy to the drug or to one of the excipients, concomitant treatment with warfarin or other vitamin K antagonists).
  • Previous exposure to ibrutinib as CLL-directed therapy.
  • Other CLL/SLL- or AIHA-directed treatment at the time of enrollment in the study, other than corticosteroids.
  • Female patients who are currently in pregnancy or are willing to be pregnant or are lactating.
Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL

Location Details

Please Choose a site

Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

Recruiting

Italy,

Hematology Osp Careggi

Firenze, Italy,

Recruiting

Italy,

Hematology Osp Maggiore della Carità

Novara, Italy,

Recruiting

Italy,

Hematology Osp Molinette

Torino, Italy,